What is The Us2.ai?
The Us2.ai is a pioneering healthtech enterprise dedicated to automating the detection and analysis of cardiovascular disease. By utilizing sophisticated artificial intelligence software, the company simplifies the complex process of echocardiography, effectively democratizing access to high-quality heart imaging. This technology addresses a critical bottleneck in clinical settings, where the interpretation of ultrasound data is often time-consuming and subject to variability. By providing automated, objective insights, The Us2.ai empowers clinicians to make faster, more accurate assessments of cardiovascular risk, ultimately improving patient outcomes and operational efficiency in hospitals and diagnostic centers worldwide.
How much funding has The Us2.ai raised?
The Us2.ai has raised a total of $15M across 1 funding round:
Series A
$15M
Series A (2022): $15M with participation from Pappas Capital, Partech International, EDBI, Sequoia India, Heal Partners, and IHH Healthcare Berhad
Key Investors in The Us2.ai
Pappas Capital
Pappas Capital is a leading healthcare venture capital firm that specializes in advancing biopharma, biotech, and medical technologies aimed at improving patient outcomes.
Partech International
Partech is a global investment firm that brings together capital, operational experience, and strategic support for entrepreneurs at seed, venture, and growth stages.
EDBI
EDBI is a global investor based in Singapore, focusing on high-growth technology sectors and catalyzing growth in fields such as biotechnology and digital health.
What's next for The Us2.ai?
With the successful closure of this major strategic investment, The Us2.ai is well-positioned to scale its enterprise-level operations and deepen its integration into global healthcare systems. The company's roadmap likely includes expanding its regulatory approvals across new international markets and enhancing its AI algorithms to cover a broader spectrum of cardiac conditions. Furthermore, the strategic backing from specialized healthcare investors suggests a focus on building long-term clinical partnerships and establishing the platform as a standard-of-care tool in cardiology departments. As the firm continues to refine its technology, the focus will shift toward proving long-term clinical utility and driving widespread adoption among healthcare providers seeking to optimize diagnostic throughput and accuracy.
See full The Us2.ai company page
